Segra Announces Election of Richard Jacinto II to Board of Directors

February 8, 2021

VANCOUVER, February 8, 2021 — Segra International Corp., an agriculture technology company, is pleased to announce that Richard Jacinto II has joined the Company’s Board of Directors after having been elected as a director at the Company’s Annual General and Special Meeting held on February 8, 2021. Richard Jacinto II CFA has been a fulltime investor in alternative medicine Companies over the past 4 years buying interests in approximately 15 private Companies. Mr. Jacinto is on the board of Steep Hill Labs and was previously on the Board of Breath of Life Pharma. Prior to investing in these Companies, Rich traded and invested in the shares of US publicly traded common stocks. He was the General Partner or Chief Investment Officer of various Investment Partnerships in the Atlas Family of Investment Partnerships since July 1995. Mr. Jacinto worked as a Vice President and Institutional Equity Salesperson at Lehman Brothers from 1984 to 1995 and at E F Hutton from 1981 to 1984. Rich received an MBA from the University of Chicago in 1981, a Bachelor of Science degree in Finance from the University of California at Berkeley in 1979, and a Chartered Financial Analyst certification in 1984.   

Richard is an accomplished executive and brings with him a wealth of experience from both the investment industry and capital markets. We are excited to welcome Richard to our Board of Directors and look forward to his contributions as Segra enters our next phase of growth. – Jamie Blundell, Chief Executive Officer.

About Segra International
Segra is an agriculture technology company offering Plant Tissue Culture services and genetics to accelerate the advancement of the cannabis industry. The Company’s Plant Tissue Culture and genomics technologies, coupled with an evolved cannabis business ecosystem, empower its clients to drive financial performance and mitigate risk, while exploring the next frontier of optimized cultivation practices for the rapidly evolving cannabis consumer. Segra has developed industrial-scale laboratories to produce disease-free, robust, and DNA fingerprinted cannabis plantlets for licensed producers globally. To support this vision, Segra has assembled a world-class team of specialists in the fields of agronomy, molecular genetics, Plant Tissue Culture, and regulatory compliance.

Contact For Further Information

Carson Otto

Carson.otto@segra-intl.com

Forward-Looking Information

This news release includes statements containing certain “forward-looking information” within the meaning of applicable securities law (“forward-looking statements”). Forward-looking statements are frequently characterized by words such as “plan”, “continue”, “expect”, “project”, “intend”, “believe”, “anticipate”, “estimate”, “may”, “will”, “potential”, “proposed” and other similar words, or statements that certain events or conditions “may” or “will” occur. These statements are only predictions. Various assumptions were used in drawing the conclusions or making the projections contained in the forward-looking statements throughout this news release. Forward-looking statements are based on the opinions and estimates of management at the date the statements are made and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable law.